Mechanisms of Mas1 Receptor-Mediated Signaling in the Vascular Endothelium

Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):433-445. doi: 10.1161/ATVBAHA.116.307787. Epub 2017 Jan 12.

Abstract

Objective: Angiotensin II (AngII) has been shown to regulate angiogenesis and at high pathophysiological doses to cause vasoconstriction through the AngII receptor type 1. Angiotensin 1 to 7 (Ang-(1-7)) acting through the Mas1 receptor can act antagonistically to high pathophysiological levels of AngII by inducing vasodilation, whereas the effects of Ang-(1-7) signaling on angiogenesis are less defined. To complicate the matter, there is growing evidence that a subpressor dose of AngII produces phenotypes similar to Ang-(1-7).

Approach and results: This study shows that low-dose Ang-(1-7), acting through the Mas1 receptor, promotes angiogenesis and vasodilation similar to a low, subpressor dose of AngII acting through AngII receptor type 1. In addition, we show through in vitro tube formation that Ang-(1-7) augments the angiogenic response in rat microvascular endothelial cells. Using proteomic and genomic analyses, downstream components of Mas1 receptor signaling were identified, including Rho family of GTPases, phosphatidylinositol 3-kinase, protein kinase D1, mitogen-activated protein kinase, and extracellular signal-related kinase signaling. Further experimental antagonism of extracellular signal-related kinases 1/2 and p38 mitogen-activated protein kinase signaling inhibited endothelial tube formation and vasodilation when stimulated with equimolar, low doses of either AngII or Ang-(1-7).

Conclusions: These results significantly expand the known Ang-(1-7)/Mas1 receptor signaling pathway and demonstrate an important distinction between the pathological effects of elevated and suppressed AngII compared with the beneficial effects of AngII normalization and Ang-(1-7) administration. The observed convergence of Ang-(1-7)/Mas1 and AngII/AngII receptor type 1 signaling at low ligand concentrations suggests a nuanced regulation in vasculature. These data also reinforce the importance of mitogen-activated protein kinase/extracellular signal-related kinase signaling in maintaining vascular function.

Keywords: angiotensin II; endothelium, vascular; phenotype; renin-angiotensin system; vasodilation.

MeSH terms

  • Angiotensin I / pharmacology
  • Angiotensin II / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Animals
  • Dose-Response Relationship, Drug
  • Electric Stimulation
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / innervation
  • Endothelium, Vascular / metabolism*
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Gene Expression Regulation
  • Male
  • Middle Cerebral Artery / drug effects
  • Middle Cerebral Artery / innervation
  • Middle Cerebral Artery / metabolism*
  • Neovascularization, Physiologic* / drug effects
  • Peptide Fragments / pharmacology
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / agonists
  • Proto-Oncogene Proteins / metabolism*
  • Rats, Sprague-Dawley
  • Receptor, Angiotensin, Type 1 / drug effects
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptors, G-Protein-Coupled / agonists
  • Receptors, G-Protein-Coupled / metabolism*
  • Signal Transduction* / drug effects
  • Signal Transduction* / genetics
  • Vasodilation* / drug effects
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Mas1 protein, rat
  • Peptide Fragments
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • Receptor, Angiotensin, Type 1
  • Receptors, G-Protein-Coupled
  • Angiotensin II
  • Angiotensin I
  • Extracellular Signal-Regulated MAP Kinases
  • p38 Mitogen-Activated Protein Kinases
  • angiotensin I (1-7)